Class II

Drug Recall: Lanreotide Injection, 120 mg/0.5 mL, 0.5 mL per pre-filled syringe, For deep subcutaneous injection, Rx Only, Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059.

Cipla USA, Inc. · January 2, 2026

Reason for Recall

Presence of Particulate Matter.

Product Description

Lanreotide Injection, 120 mg/0.5 mL, 0.5 mL per pre-filled syringe, For deep subcutaneous injection, Rx Only, Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059. NDC: 69097-870-67

Distribution

Nationwide in the USA

States Affected

NATIONWIDE

Quantity Affected

15,221 syringes

Source: FDA (openFDA Drug Enforcement)

Recall number: D-0290-2026

Status: ongoing

SafeCheck provides drug interaction information from FDA-approved product labeling (openFDA). This is for informational purposes only and is not medical advice. Always consult your healthcare provider before making medication decisions.